Aug 03, 2022 4:05pm EDT Societal CDMO to Report Financial Results for Second Quarter 2022 on August 10, 2022
Jul 20, 2022 7:00am EDT Societal CDMO Selected To Provide Tech Transfer And Manufacturing Services To Support Clinical Development Of An Oral Solid Dose Product In Europe
Jul 12, 2022 7:00am EDT Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR Products
Jun 08, 2022 7:00am EDT Societal CDMO Announces Key New Customer Project Within Automated Fill/Finish and Lyophilization Unit at San Diego Facility
Jun 01, 2022 7:00am EDT Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer’s Disease Treatment, AD101
May 17, 2022 7:00am EDT Societal CDMO Unveils “20/80 Second Source Technical Transfer” Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing
May 05, 2022 7:00am EDT Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in Europe